Capricor Therapeutics Shareholders Encouraged to Join Securities Fraud Class Action Lawsuit

Overview of the Case

On September 8, 2026, Schall, Brown & Schwartz LLP (SBS), a prominent litigation firm representing shareholders, announced that investors have the opportunity to lead a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). This lawsuit pertains to allegations of securities fraud under the Securities Exchange Act of 1934, specifically violations of §§10(b) and 20(a), and Rule 10b-5, which addresses provisions related to misleading statements in the context of securities. The class period for this action spans from December 17, 2025, to July 26, 2026, and the deadline for potential lead plaintiffs to step forward is September 28, 2026.

Significance of the Class Action

The importance of class action lawsuits lies in their ability to unite shareholders who have suffered losses due to corporate misconduct. In this instance, Capricor is alleged to have made false and misleading statements regarding its clinical data for Deramiocel, a biologic product. Specifically, the company is accused of changing the statistical analysis plan without prior agreement from the FDA. This raises serious questions about the validity of the evidence provided to support their drug development, leading to potential disillusionment among investors when the truth was revealed.

The Allegations

The lawsuit claims that Capricor misrepresented key facts which misled investors and caused them to incur financial losses. In this case, the company’s shift in approach to the statistical analysis of clinical data appeared to underplay risks associated with the FDA's approval processes. Understanding the implications of these allegations is crucial for shareholders, especially those who purchased stock during the stipulated class period.

Potential for Recovery

For those shareholders who lost money on their investment in Capricor during the class period, this lawsuit offers a path towards recovery of those losses. Participation in the class action does not require being appointed as a lead plaintiff; any affected shareholders can contribute to the case and stand to gain recompense based on a potential favorable outcome.

Why SBS?

Schall, Brown & Schwartz LLP stands out due to its commitment to advocating for shareholder rights. The firm showcases a strong record in securities class action lawsuits, ensuring that the interests of investors are vigorously defended. Founding partners Brian Schall, Andrew Brown, and David Schwartz bring an extensive wealth of experience to the case, making SBS a trusted advocate for individuals seeking justice.

Next Steps for Shareholders

A critical aspect of this situation is that the class has yet to be certified by the court. Until such certification occurs, investors are not technically represented by an attorney. This means that active participation is encouraged for those wishing to pursue their rights and seek recovery for their losses. Interested shareholders are urged to contact SBS directly through their offices—in particular, Brian Schall or David Schwartz—at their Los Angeles location. The firm offers complimentary consultations to discuss the situation and next potential steps, ensuring shareholders are informed and empowered.

Conclusion

The Capricor Therapeutics case serves as a stark reminder of the importance of transparency and accountability within the pharmaceutical industry. As the saga unfolds, investors are encouraged to take action and have their voices heard. By joining the class action, they may not only reclaim lost investments but also contribute to broader efforts for corporate accountability.

For further information and assistance regarding the case, you can reach Schall, Brown & Schwartz LLP at their website www.schallfirm.com or call 310-301-3335.